Evidence map›Paper›PMID 36354663›Full record

ReviewCurrent issues in molecular biology2022

Apoptotic MSCs and MSC-Derived Apoptotic Bodies as New Therapeutic Tools.

Irina V Kholodenko, Roman V Kholodenko, Alexander G Majouga, Konstantin N Yarygin

Open access · goldAbstract readReview
In one paragraph

Review in Current issues in molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Anastasis: Reality or Fiction?Bulletin of experimental biology and medicine · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Irina V KholodenkoLaboratory of Cell Biology, Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.ORCID 0000-0002-4079-5210
Roman V KholodenkoLaboratory of Molecular Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.ORCID 0000-0001-6083-6588
Alexander G MajougaFaculty of Chemical and Pharmaceutical Technologies and Biomedical Products, Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russia.
Konstantin N YaryginLaboratory of Cell Biology, Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.ORCID 0000-0002-2261-851X
Institute of Biomedical Chemistry · RUD. Mendeleyev University of Chemical Technology of Russia · RUInstitute of Bioorganic Chemistry · RU

Funding

The Ministry of Science and Higher Education of Russian Federation 075-15-2020-792 (unique identifier RF--190220X0031)
6 · The paper itself

Abstract

Over the past two decades, mesenchymal stem cells (MSCs) have shown promising therapeutic effects both in preclinical studies (in animal models of a wide range of diseases) and in clinical trials. However, the efficacy of MSC-based therapy is not always predictable. Moreover, despite the large number of studies, the mechanisms underlying the regenerative potential of MSCs are not fully elucidated. Recently, it has been reliably established that transplanted MSCs can undergo rapid apoptosis and clearance from the recipient's body, still exhibiting therapeutic effects, especially those associated with their immunosuppressive/immunomodulating properties. The mechanisms underlying these effects can be mediated by the efferocytosis of apoptotic MSCs by host phagocytic cells. In this concise review, we briefly describe three types of MSC-generated extracellular vesicles, through which their therapeutic functions can potentially be carried out; we focused on reviewing recent data on apoptotic MSCs and MSC-derived apoptotic bodies (MSC-ApoBDs), their functions, and the mechanisms of their therapeutic effects.

Indexed as

apoptosisapoptotic bodiesextracellular vesiclesimmunomodulationmesenchymal stem/stromal cellsMSC-based therapyprogrammed cell death

Identifiers

PMID36354663
PMCPMC9688732
OpenAlexW4307273489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.